Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of abemaciclib on patients' roles and responsibilities
ISRCTN17281696Phase 4Completed
- Sponsor
- University of Sussex
- Start
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by University of Sussex. Primary endpoints: Quality of life at 6 months and Role function at 6 months. Started Sep 2020; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN17281696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17281696.